



21 September 2018

RESPIRI COMMERCIALISATION STRATEGY GATHERS MOMENTUM

HEALTHCARE INVESTOR DAY, SINGAPORE, 12 SEPTEMBER

PROF BRUCE THOMPSON TO CHAIR AUSTRALIAN MEDICAL & SCIENTIFIC
ADVISORY BOARD

FIRST EXHIBIT AT THE MEDTECH CONFERENCE, PHILADELPHIA 24-26 SEPTEMBER

MEDICAL & SCIENTIFIC ADVISORY BOARD MEETING, LONDON 29 OCTOBER

CONSUMER CAMPAIGN PILOT TO KICK OFF

UPDATE TO CEO'S '100 DAY' PRESENTATION

SINGAPORE | GATEWAY TO EMERGING MARKETS OF ASIA

On 12 September, CEO, Mario Gattino presented at the Spark+ Healthcare Investor Day in Singapore. It was an opportunity to introduce Respiri to leading Singapore-based hedge funds, family offices and institutional investors and hold a series of one on one investor meetings. Singapore is the gateway to the emerging markets of Asia and the Middle East, and through government backed initiatives, is the new Asian capital for medtech development.

Mario Gattino said, 'Respiri's technology was very well received by investors at the meeting, particularly because Singapore itself is one of the highest asthma prevalence communities in the world. Alarming, 20% of children have asthma. The global average is 14%. With a superior healthcare system and a motivated population with means, Singapore is a great testing ground for our product.'

Respiri has included Singapore, along with Australia and the UK, in an online marketing survey of parents of children with asthma scheduled to roll out next week and looks forward to reporting on progress now relationships have been established in that country.

PROFESSOR BRUCE THOMPSON TO CHAIR RESPIRI'S AUSTRALIAN MEDICAL & SCIENTIFIC ADVISORY BOARD



The company is highly encouraged by the support of Professor Bruce Thompson who has been appointed chair of Respiri's Australian Medical and Scientific Advisory Board and Product Portfolio Development Lead. He is Professor of Allergy, Immunology and Respiratory Medicine at the Central Clinical School, Monash University and Alfred Health, and Head of Physiology Services at the Alfred Hospital, the biggest in the country, where his group performs lung function tests on more than 7,000 patients per year.

Professor Thompson is also the **President elect** of the **Thoracic Society of Australia and New Zealand**, the only peak body to represent all professional groups with an interest in improving knowledge and understanding of lung disease across Australia and New Zealand.

Speaking from the European Respiratory Society International Congress 2018 in Paris, Professor Thompson said, 'I'm excited about the potential of Respi's wheeze detection technology and the opportunity to play a role in the research and development of the company's product portfolio. With only 1 in 10 asthma patients well controlled, we see far too many children and adults presenting to our emergency departments. If we can do something to reduce those numbers with digital tools to make it easier to monitor symptoms at home, it will be a truly significant breakthrough for asthma management.'

THE MEDTECH CONFERENCE | THE LEADING NORTH AMERICAN GATHERING OF GLOBAL MEDTECH EXECUTIVES

With three thousand senior medtech executives and decision makers in attendance, the MedTech Conference provides intensive networking opportunities for Respi to connect with international specialists in policy, innovation business development and investment. Held in Philadelphia, Respi's booth is well located to attract the attention of global medtech players. Mario Gattino and Chief Research Officer, Dr Samaneh Sarraf will be joined by a representative from Two Bulls' New York office to demonstrate the Gen II prototype. This is the first time that the company will have a booth at this most significant medtech conference and as we approach the pre-production phase of development, the timing is perfect.

Following the conference, the Respi team will visit the Scripps Translational Science Institute (STSI) in San Diego to provide Steven Steinhubl MD, Director of Digital Medicine and Donald Jones, Chief Digital Officer with a product development update. Discussions with Scripps commenced earlier this year on the CEO's last visit to the U.S.


As reported to the market on 30 May, these global leaders in digital medicine believe Respi's technology to be unique and recognise its potential to collect data and help people with asthma and healthcare providers better manage their disease. In 2016, STSI was awarded a grant for over \$200m by the National Institutes of Health's Precision Medicine Initiative to lead the 'All of Us' Research Program's Participant Center. Recently launched, the research program heralds a new era for technology-driven citizen science and precision medicine, and STSI heads key aspects of the initiative, including the integration of mobile health technologies. The potential for Respi to engage in studies with the world-renowned Scripps Translational Science Institute cannot be over-estimated as the company develops plans to launch in this important market.



OVERVIEW



FACTS-AT-A-GLANCE



KEY OPINION LEADERS GATHER FOR FIRST MEETING OF MEDICAL AND SCIENTIFIC ADVISORY BOARD IN LONDON

Following meetings in the UK, Respiro advised shareholders on 30 May, of the commitments gained from leading universities and research institutes to perform studies and clinical trials. We are pleased to announce that the first Medical and Scientific Advisory Board meeting will take place in London on 29 October. The delegates will review asthma interventions in the UK and discuss how Respiro's breakthrough technology can help improve patient outcomes, as well as finalise recommendations for the study protocols. The planned studies are required for our product's appraisal by the Health Technology Assessment (HTA) and the National Institute for Health and Care Excellence (NICE), the public body serving the National Health System (NHS) responsible for published guidelines in health technologies, clinical practice, health promotion and social care services.

Confirmed delegates include; Dr Mark Levy, Respiratory Lead for Harrow CCG, Professor Aziz Sheikh OBE, Usher Institute, Edinburgh, Scotland, Professor Jonathan Grigg, Paediatric Respiratory & Environmental Medicine, Queen Mary University of London, Professor Anoop Chauhan, Severe Asthma Centre, Portsmouth, Dr Katy Pike, Paediatric Respiratory, Great Ormond Street Hospital, London, Dr Paul Seddon, Paediatric Respiratory, Royal Alexandra Children's Hospital, Brighton, Dr Louise Fleming, Paediatric Respiratory, Royal Brompton and Harefield Hospitals, London and digital wheeze detection pioneer, Professor Simon Godfrey. We look forward to updating shareholders on the outcomes of this milestone meeting.



Dr Mark Levy



Prof Aziz Sheikh OBE



Prof Jonathan Grigg



Dr Louise Fleming

CONSUMER CAMPAIGN PILOT TO KICKOFF

Respiro will commence the company's go-to-market strategy with a compelling awareness campaign targeting parents of children with asthma and healthcare providers who are seeking new information and new solutions. Starting with a pilot in Australia, the objective of the campaign is to capture meaningful data to inform our ongoing marketing efforts through greater understanding of the needs of the asthma community; customers, GPs and pharmacists.

This first phase will capture pre-registrations to create a groundswell early. By creating a relationship with our target audience now, we will better understand the customer journey from first exposure, to promotion, through to purchase and daily use. Using this pre-registration strategy, we expect to secure early sales and provide the social proof to accelerate future sales.

What makes successful brands is collaboration with a best in class customer engagement business and we look forward to announcing a new partnership to implement our Australian pilot and marketing efforts in the coming weeks.



UPDATE TO CEO'S '100 DAY' PRESENTATION

Attached to this announcement is the latest update to the CEO's '100 Day' presentation, dated 5 March 2018. Featuring a technology update from Grey Innovation and Two Bulls, as promised in our announcement a fortnight ago, this is the presentation that will be shared with some of the Melbourne-based shareholders today as we trial a new face-to-face engagement format for investors.

Based on the group's feedback, it is the company's intention to offer the event in Sydney and Brisbane so everyone has the opportunity to meet with the management team and our key technology partners.

—END—

Contact:
Mario Gattino
CEO & Director
+61 3 9653 9160



About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.